Can an India-Made Shot Protect Against Congo’s Ebola Virus?

In Pune, the factory ran ahead of the trial. Serum Institute made doses while Oxford was beginning to test the shot in people. The idea was to have supplies ready if the vaccine worked. In the Democratic Republic of the Congo, researchers now have a chance to answer that question where people are already being exposed to the virus.

What just changed for the India-made Ebola shot?

On November 4, the World Health Organization said its advisers had recommended adding the Oxford–Serum Institute vaccine, ChAdOx1 BDBV, and Moderna’s mRNA-1469 to Congo’s ongoing Tumaini trial. Both were designed for Bundibugyo. WHO said they would enter the trial after national approvals. As of November 6, the publicly confirmed step was the recommendation to test them.

How big is Congo’s outbreak now?

The Democratic Republic of the Congo declared the outbreak in May. By November 3, it had recorded 10,668 confirmed cases and 5,198 deaths across eight provinces, according to the European Centre for Disease Prevention and Control’s November 5 update. Ituri and North Kivu account for most of the confirmed cases. On November 5, Britain said a doctor who contracted Ebola while working on the response had been flown to London for specialist care.

What is Bundibugyo, and how does it spread?

Bundibugyo is one of several related viruses that can cause Ebola disease. It can spread when blood or other bodily fluids from someone who is sick or has died come into direct contact with another person, or through contaminated items such as bedding. Early symptoms can include fever and fatigue. The name matters because the available vaccine was developed for a different member of the same virus family.

Don’t we already have an Ebola vaccine?

Yes. Merck’s Ervebo is licensed against the Zaire Ebola virus, which caused the large West African outbreak a decade ago. A vaccine trains the immune system to recognise particular features of a virus. With Bundibugyo, researchers have to test whether the features Ervebo teaches the body to recognise are similar enough to offer protection. There’s still no licensed vaccine for Bundibugyo.

Then why is Congo’s trial already using Ervebo?

Ervebo was the first shot tested in Tumaini. A participant in Bunia received it on October 23. The study is testing for cross-protection, meaning whether a shot built for one virus also helps against a related one. The Oxford–Serum Institute and Moderna shots would let researchers ask a different question in the same trial: how well do vaccines designed specifically for Bundibugyo work?

How does the India-made shot work?

It uses the same delivery technology as the Oxford–AstraZeneca COVID-19 vaccine. Think of a modified adenovirus as a courier. It carries instructions that tell cells to make a protein found on the surface of Bundibugyo. The immune system gets a chance to recognise that protein ahead of a possible encounter with the virus. The delivery method is familiar. The protein it teaches the body to recognise is different.

What do we know from the tests so far?

Early human trials began in Britain in July and Uganda in October. They were designed to see how well volunteers tolerated the shot and whether it produced an immune response. WHO’s advisers reviewed interim early-trial data and animal studies before recommending the next step. An immune response tells scientists the body noticed the vaccine. The Congo trial can show whether fewer vaccinated people actually fall ill.

How do you test a shot in the middle of an outbreak?

Start with one confirmed patient. A team traces people who may have been exposed, such as members of the household and people who cared for the patient. That group forms a ring. Eligible contacts can volunteer for the trial, and researchers compare how often people in the different study groups develop confirmed Bundibugyo disease. It puts the study where the risk is highest.

What did India contribute?

Oxford scientists developed the shot and prepared the material needed to start making it at scale. Pune’s Serum Institute says it manufactured and stockpiled about 620,000 doses in two weeks. It also supplied investigational doses for the British and Ugandan studies. That stockpile is a head start on supply if the shot works and regulators clear it for use.

What can health workers do while they wait?

They can test suspected cases, trace contacts, care for patients early and make burials safer. In Mongbwalu, Ituri, Ebola survivor Francine Mave reportedly told WHO, “I hid because I was convinced that nobody comes out alive from the centre.” She sought care after a visit from local researcher Alain Alithum and recovered. Finding people early also depends on whether they trust the person at their door.

When could we know whether the shot protects people?

WHO expects results from the vaccine trial in early 2027. That’s the timetable for evidence from the study. A public rollout would be a separate decision based on what the trial finds about protection and safety. Pune has shown how fast it can make the doses. Bunia is where researchers are trying to find out what those doses can do.